PremiumCompany AnnouncementsCybin Supports FDA’s Push for Psychedelic Research VA secretary wants to find answers on psychedelics therapies, Politico says Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results PremiumThe FlyCybin announces USPTO patent in support of CYB003 program Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs PremiumThe FlyPsychedelic: Exclusive talk with retreat provider ONE Retreats Psychedelic: Exclusive talk with biotech company Clearmind Medicine Psychedelic: atai Life Sciences, NRx report quarterly results